Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2011

01-08-2011 | Research Article

Telomerase reverse transcriptase catalytic subunit expression and proliferation index in Wilms tumor

Authors: Gulden Diniz, Safiye Aktas, Aysen Turedi, Gunyuz Temir, Ragip Ortac, Canan Vergin

Published in: Tumor Biology | Issue 4/2011

Login to get access

Abstract

Telomerase activity provides telomere maintenance in chromosomes. It prevents cells from entering senescence. Telomerase activity is one of the crucial steps in various cancers. Wilms tumor (nephroblastoma) is one of the most common solid tumors of childhood. Hitherto, telomerase reverse transcriptase (TERT) catalytic subunit expression in Wilms tumor has not been investigated widely. The aim of this study was to explore the expression level of human TERT in Wilms tumor and to correlate with some clinical prognosis factors such as tumor weight, stage, histology, and Ki67 expression. This study included 41 nephroblastoma cases of childhood. The telomerase catalytic subunit expression and proliferation index was determined using an immunohistochemical method on archival paraffin-embedded tissue sections. Statistical analysis was done on SPSS 9.05 by Mann–Whitney U test and Spearman’s correlation analysis. TERT expression was negative in 11 cases (26.8%), weakly positive in 14 cases (34.1%), and strongly positive in 16 cases (39%). The proliferation index was found to be 20 to 90 (mean 58.9 ± 26.8). Using Spearman correlation analysis, both the TERT expression (p = 0.032) and Ki67 index (p = 0.048) were found to be correlated with survival rate. Similarly, both the telomerase expression (p = 0.011) and the Ki67 index (0.040) were correlated with the weight and dimension of the tumor. But there was no relationship between telomerase expression and Ki67 index (p = 0.429). The mean survival time for telomerase negative cases was 56.6 ± 27.3 months, while it was 34.67 ± 28.36 months for positive cases. The Mann–Whitney U test revealed that levels of telomerase (p = 0.040) significantly affected the survival rate. In the present study, we showed that the presence of TERT expression correlated with both tumor size and survival time. These findings suggest that senescence may play an important role in WT evolution, and determination of telomere maintenance will be useful to predict survival and follow-up of patients with Wilms tumor.
Literature
1.
2.
Hiyama E, Yamaoka H, Matsunaga T, Hayashi Y, Ando H, Suita S, et al. High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma. Br J Cancer. 2004;91(5):972–9.PubMed
3.
Cukusić A, Skrobot Vidacek N, Sopta M, Rubelj I. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res. 2008;122(3–4):263–72.PubMed
4.
Cakir C, Gulluoglu MG, Yilmazbayhan D. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology. 2006;38(1):10–5.PubMedCrossRef
5.
6.
Hiyama E, Hiyama K, Yokoyama T, Shay JW. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia. 2001;3(1):17–26.PubMedCrossRef
7.
Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, et al. Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery. 2008;143(1):113–25.PubMedCrossRef
8.
Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, et al. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res. 2010;34:1320–4.PubMedCrossRef
9.
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.PubMedCrossRef
10.
Jurić I, Pogorelić Z, Kuzmić-Prusac I, Biočić M, Jakovljević G, Stepan J, et al. Expression and prognostic value of the Ki-67 in Wilms’ tumor: experience with 48 cases. Pediatr Surg Int. 2010;26:487–93.PubMedCrossRef
11.
Scott RH, Walker L, Olsen ØE, Levitt G, Kenney I, Maher E, et al. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child. 2006;91(12):995–9.PubMedCrossRef
12.
Husain AN, Pysher TJ, Dehner LP. The kidney and lower urinary tract. In: Stocker JT, Dehner LP, editors. Pediatric pathology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 834–903.
13.
Perlman EJ. Renal tumors. In: Gilbert-Barness E, editor. Potter’s pathology of the fetus, infant and child. Philadelphia: Mosby Elsevier; 2007. p. 1347–75.
14.
Argani P, Beckwith JB. Renal neoplasms of childhood. In: Mills SE, editor. Sternberg’s diagnostic surgical pathology. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 2001–33.
15.
16.
Terenziani M, Spreafico F, Collini P, Piva L, Perotti D, Podda M, et al. Adult Wilms’ tumor: a monoinstitutional experience and a review of the literature. Cancer. 2004;101(2):289–93.PubMedCrossRef
17.
Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet. 2006;43(9):705–15.PubMedCrossRef
18.
Hohenstein P, Hastie ND. The many facets of the Wilms’ tumour gene, WT1. Hum Mol Genet. 2006;15(Spec No 2):R196–201.PubMedCrossRef
19.
Maw MA, Grundy PE, Millow LJ, Eccles MR, Dunn RS, Smith PJ, et al. A third Wilms’ tumor locus on chromosome 16q. Cancer Res. 1992;52(11):3094–8.PubMed
20.
Rahman N, Arbour L, Tonin P, Renshaw J, Pelletier J, Baruchel S, et al. Evidence for a familial Wilms’ tumour gene (FWT1) on chromosome 17q12–q21. Nat Genet. 1996;13(4):461–3.PubMedCrossRef
21.
Miozzo M, Perotti D, Minoletti F, Mondini P, Pilotti S, Luksch R, et al. Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors. Genomics. 1996;37(3):310–5.PubMedCrossRef
22.
White GR, Kelsey AM, Varley JM, Birch JM. Somatic glypican 3 (GPC3) mutations in Wilms’ tumour. Br J Cancer. 2002;86(12):1920–2.PubMedCrossRef
23.
Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007;315(5812):642–5.PubMedCrossRef
24.
Slade I, Stephens P, Douglas J, Barker K, Stebbings L, Abbaszadeh F, et al. Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene. J Med Genet. 2010;47(5):342–7.PubMedCrossRef
25.
Ramachandran C, Melnick SJ, Escalon E, Jhabvala P, Khatib Z, Alamo A, et al. Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric Wilms’ tumors. Anticancer Res. 2000;20(5C):3759–65.PubMed
26.
Ramburan A, Hadley GP, Govender D. Expression of E-cadherin, cadherin-11, alpha-, beta- and gamma-catenins in nephroblastomas: relationship with clinicopathological parameters, prognostic factors and outcome. Pathology. 2006;38(1):39–44.PubMedCrossRef
27.
Wittmann S, Wunder C, Zirn B, Furtwängler R, Wegert J, Graf N, et al. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer. 2008;47(5):386–95.PubMedCrossRef
28.
Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, et al. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms’ tumor. Cancer Res. 1999;59(17):4301–7.PubMed
29.
Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman EJ, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms’ tumor. J Clin Oncol. 2005;23(36):9138–45.PubMedCrossRef
30.
Yashima K, Maitra A, Timmons CF, Rogers BB, Pinar H, Shay JW, et al. Expression of the RNA component of telomerase in Wilms tumor and nephrogenic rest recapitulates renal embryogenesis. Hum Pathol. 1998;29(5):536–42.PubMedCrossRef
31.
Green DM, D’Anjio GJ, Beckwith JB. Wilms’ tumor. In: Pizzo PA, Fobcek DG, editors. Principles and practice of pediatric oncology. 2nd ed. Philadelphia: Lippincott; 1997. p. 733–59.
32.
Williams G. Statistical methods. In: Detels R, Beaglehole R, Lansung MA, Gulliford M, editors. Oxford textbook of public health: epidemiological and biostatistical approaches, vol. 2. 5th ed. England: Oxford Press; 2009. p. 448–714.
33.
Horster MF, Braun GS, Huber SM. Embryonic renal epithelia: induction, nephrogenesis, and cell differentiation. Physiol Rev. 1999;79:1157–91.PubMed
34.
Quaggin SE, Kreidberg JA. Development of the renal glomerulus: good neighbors and good fences. Development. 2008;135(4):609–20.PubMedCrossRef
35.
Fischer EG, Carney JA, Anderson SR, Klatt EC, Lager DJ. An immunophenotypic comparison of metanephric metaplasia of Bowman capsular epithelium with metanephric adenoma, Wilms tumor, and renal development: a case report and review of the literature. Am J Clin Pathol. 2004;121(6):850–6.PubMedCrossRef
36.
Delahunt B, Farrant GJ, Bethwaite PB, Nacey JN, Lewis ME. Assessment of proliferative activity in Wilms’ tumour. Anal Cell Pathol. 1994;7(2):127–38.PubMed
37.
Berrebi D, Leclerc J, Schleiermacher G, Zaccaria I, Boccon-Gibod L, Fabre M, et al. High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma. PLoS One. 2008;3(5):e2216.PubMedCrossRef
38.
Khine MM, Aung W, Sibbons PD, Howard CV, Clapham E, McGill F, et al. Analysis of relative proliferation rates of Wilms’ tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index. Lab Invest. 1994;70(1):125–9.PubMed
39.
Oh S, Song Y, Yim J, Kim TK. The Wilms’ tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem. 1999;274(52):37473–8.PubMedCrossRef
40.
Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature. 2009;460(7251):66–72.PubMedCrossRef
Metadata
Title
Telomerase reverse transcriptase catalytic subunit expression and proliferation index in Wilms tumor
Authors
Gulden Diniz
Safiye Aktas
Aysen Turedi
Gunyuz Temir
Ragip Ortac
Canan Vergin
Publication date
01-08-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0178-1

Other articles of this Issue 4/2011

Tumor Biology 4/2011 Go to the issue

Research Article

Detection of viral DNA sequences in sporadic colorectal cancers in relation to CpG island methylation and methylator phenotype

Research Article

Ezrin mRNA target site selection for DNAzymes using secondary structure and hybridization thermodynamics

Research Article

Sp1 inhibition-mediated upregulation of VEGF165b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549

Research Article

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response

Research Article

Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)

Research Article

Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits